Sei Investments CO Arvinas, Inc. Transaction History

Sei Investments CO

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$24.46 - $40.4 $51,194 - $84,557	2,093 Added 8.54%	26,594 $707,000
Q1 2024 May 07, 2024	BUY	$36.38 - $52.31 $612,311 - $880,429	16,831 Added 219.44%	24,501 $1.01 Million
Q4 2023 Feb 14, 2024	BUY	$14.19 - $42.33 $108,837 - $324,671	7,670 New	7,670 $315,000
Q2 2023 Aug 11, 2023	BUY	$21.73 - $31.43 $1,282 - $1,854	59 Added 0.6%	9,908 $245,000
Q1 2023 May 12, 2023	BUY	$26.15 - $37.26 $257,551 - $366,973	9,849 New	9,849 $269,000
Q3 2022 Nov 14, 2022	BUY	$41.87 - $57.99 $97,766 - $135,406	2,335 Added 15.97%	16,958 $755,000
Q2 2022 Aug 15, 2022	BUY	$36.01 - $74.24 $526,574 - $1.09 Million	14,623 New	14,623 $614,000
Q1 2022 May 13, 2022	SELL	$60.27 - $81.57 $326,181 - $441,456	-5,412 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$65.85 - $96.21 $746,212 - $1.09 Million	-11,332 Reduced 67.68%	5,412 $441,000
Q3 2021 Nov 12, 2021	BUY	$73.2 - $107.87 $719,702 - $1.06 Million	9,832 Added 142.25%	16,744 $1.38 Million
Q2 2021 Aug 06, 2021	SELL	$60.45 - $84.26 $295,116 - $411,357	-4,882 Reduced 41.39%	6,912 $532,000
Q4 2020 Feb 08, 2021	BUY	$20.19 - $84.93 $238,120 - $1 Million	11,794 New	11,794 $1 Million

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.02B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Sei Investments CO, based on Form 13F filings with the SEC.

Stay updated on Sei Investments CO with notifications on news.